CompleWare and VIDA announce a joint marketing agreement promoting complementary respiratory services. Their partnership will deploy a best-in-class pulmonary platform and excellence in clinical trial management, with precision, ISO-certified core lab imaging.
“CompleWare and VIDA provide unique service offerings in the respiratory therapeutic area,” said Dr. John M. Weiler, CompleWare’s President. “Their synergy will lead to a strong joint value proposition to customers.”
CompleWare software and contract research organization (CRO) services will facilitate complete respiratory development programs. This will provide specialized and insightful experts to support global respiratory trials. VIDA and CompleWare will provide precision lung imaging informatics, delivered through core lab imaging services (Precision Services) and interactive software (VIDA|vision). This solution spans the care cycle, from detection through treatment across a range of pulmonary diseases: COPD (including severe emphysema, chronic bronchitis), lung cancer, and asthma.
CompleWare and VIDA offer unprecedented pulmonary expertise. CompleWare has provided services to the pharmaceutical industry for the collection and management of clinical trial data for >30 years. Drawing on multi-disciplinary expertise in pulmonology, radiology, and electrical and biomedical engineering, VIDA has become an innovator in precision pulmonary imaging. VIDA has supported numerous academic and industry trials for >10 years, cited in >200 peer-reviewed publications.
The CompleClinical application is a comprehensive eClinical solution for clinical trial data capture and management. The VIDA|vision pulmonary suite of software and services provides unparalleled breadth and depth of analysis, empowering chest physicians with advanced, quantitative information to help inform care decisions.
"We are thrilled to be partnering with CompleWare, merging our advanced quantitative lung imaging with expert respiratory trial management to offer a great dynamic to meet the endpoints of tomorrow's pulmonary medicine," said Jered Sieren, Director of Clinical Research & Development at VIDA.
